Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SPR | P35270 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533899 | 0.86 | MTNR1A (0.57) | P2RX7NOTUMMTNR1AMTNR1BKMT2A | |
| SCHEMBL23093435 | 0.83 | P2RX7 (0.55) | P2RX7PKMKMT2ANPC1RAB9A | |
| SCHEMBL3637948 | 0.83 | MTNR1A (0.43) | P2RX7PKMNOTUMMTNR1AMTNR1B | |
| SCHEMBL17699770 | 0.83 | GLA (0.47) | P2RX7NOTUMMTNR1AMTNR1BPOLB | |
| SCHEMBL19376791 | 0.81 | HPGD (0.49) | MTNR1AMTNR1BKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL27611366 | 0.81 | HPGD (0.49) | P2RX7POLBKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3635747 | 0.79 | NQO2 (0.49) | P2RX7NOTUMMTNR1AMTNR1BPOLB | |
| SCHEMBL14631807 | 0.78 | RAB9A (0.41) | PKMMTNR1AMTNR1BKMT2ANPC1 | |
| SCHEMBL8361456 | 0.78 | FFAR1 (0.51) | PKMPOLB | |
| SCHEMBL29782739 | 0.78 | FFAR1 (0.51) | PKMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063035-B2 | Triazolyl aminopyrimidine compounds | ELI LILLY AND COMPANY (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100087431-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087431-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | DPYD, TP53, TYMP | P2RX7 1403/4885PKM 1694/4885NOTUM 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.